Dr. Christopher J. Forlenza
Claim this profileMemorial Sloan Kettering Cancer Center
Expert in Lymphoma
Expert in Histiocytic Disorders
18 reported clinical trials
38 drugs studied
About Christopher J. Forlenza
Education:
- Earned an MD (Doctor of Medicine) from an unspecified medical school.
Experience:
- Serves as a Pediatric Hematologist-Oncologist at Memorial Sloan Kettering Cancer Center, with a specialization in pediatric lymphomas.
- An integral part of the Pediatric Lymphoma Service team, focusing on comprehensive care for children, adolescents, and young adults.
- Works closely with a multidisciplinary team to ensure holistic care and support for patients and their families.
Area of expertise
1Lymphoma
Global LeaderStage IV
Stage I
Stage II
2Histiocytic Disorders
Global LeaderStage I
Stage II
MTOR positive
Affiliated Hospitals
Clinical Trials Christopher J. Forlenza is currently running
DAY101
for Langerhans Cell Histiocytosis
This trial tests the safety and effectiveness of tovorafenib (DAY101) in children and young adults with Langerhans cell histiocytosis that is worsening, has returned, or does not respond to other treatments. Tovorafenib is taken orally and works by blocking enzymes needed for cancer cell growth. The study aims to find the best dose and observe the response and side effects over time.
Recruiting1 award Phase 228 criteria
Brentuximab Vedotin + Nivolumab
for Hodgkin's Lymphoma
This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stage I and II classical Hodgkin lymphoma. Brentuximab vedotin is in a class of medications called antibody-drug conjugates. It is made of a monoclonal antibody called brentuximab that is linked to a cytotoxic agent called vedotin. Brentuximab attaches to CD30 positive lymphoma cells in a targeted way and delivers vedotin to kill them. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs such as doxorubicin hydrochloride, bleomycin sulfate, vinblastine sulfate, dacarbazine, and procarbazine hydrochloride work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. Vincristine is in a class of medications called vinca alkaloids. It works by stopping cancer cells from growing and dividing and may kill them. Prednisone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Adding immunotherapy to the standard treatment of chemotherapy with or without radiation may increase survival and/or fewer short-term or long-term side effects in patients with classical Hodgkin lymphoma compared to the standard treatment alone.
Recruiting2 awards Phase 3
More about Christopher J. Forlenza
Clinical Trial Related8 years of experience running clinical trials · Led 18 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Christopher J. Forlenza has experience with
- Nivolumab
- Brentuximab Vedotin
- Larotrectinib
- Palbociclib
- Erdafitinib
- Selpercatinib
Breakdown of trials Christopher J. Forlenza has run
Lymphoma
Histiocytic Disorders
Langerhans Cell Histiocytosis
Cystic Tumor
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Christopher J. Forlenza specialize in?
Christopher J. Forlenza focuses on Lymphoma and Histiocytic Disorders. In particular, much of their work with Lymphoma has involved Stage IV patients, or patients who are Stage I.
Is Christopher J. Forlenza currently recruiting for clinical trials?
Yes, Christopher J. Forlenza is currently recruiting for 3 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Christopher J. Forlenza has studied deeply?
Yes, Christopher J. Forlenza has studied treatments such as Nivolumab, Brentuximab Vedotin, Larotrectinib.
What is the best way to schedule an appointment with Christopher J. Forlenza?
Apply for one of the trials that Christopher J. Forlenza is conducting.
What is the office address of Christopher J. Forlenza?
The office of Christopher J. Forlenza is located at: Memorial Sloan Kettering Cancer Center, New York, New York 10065 United States. This is the address for their practice at the Memorial Sloan Kettering Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.